Hospital
Altru Health System
Altru Health System was paid $18.68M by Medicaid between Jan 2018 and Dec 2024, across 215 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoALTRU HEALTH SYSTEM
GRAND FORKS, ND 58201
GRAND FORKS, ND 58201
33aNPI1154346161assigned 07/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.68M
24GClaims326,692
24DCodes billed215
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Dakota
Rank by total paid#3 of 8
Median peer was paid$750K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 71,350 | $2.08M | |
| 2019 | 30,704 | $1.63M | |
| 2020 | 20,992 | $1.13M | |
| 2021 | 47,835 | $3.60M | |
| 2022 | 51,257 | $3.39M | |
| 2023 | 58,390 | $3.83M | |
| 2024incomplete | 46,164 | $3.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 19,915 | 18,458 | $3.17M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 14,468 | 13,174 | $2.95M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 12% | 7,297 | 5,602 | $2.28M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 12% | 6,492 | 5,365 | $2.21M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 7.4% | 21,632 | 4,219 | $1.39M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.2% | 17,857 | 3,741 | $1.34M |
| A0425 | Ground mileage, per statute mile | 5.0% | 15,257 | 11,254 | $926K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.2% | 27,401 | 21,240 | $786K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 4,616 | 4,330 | $539K |
| A0998 | Ambulance response and treatment, no transport | 2.8% | 2,649 | 1,658 | $528K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.7% | 6,700 | 6,356 | $317K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 5,927 | 1,741 | $308K |
203 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 8,437 | $288K |
| 99285 | Emergency room visit (most serious) | 1.2% | 1,121 | $231K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 234 | $133K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,238 | $73K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 135 | $73K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 106 | $71K |
| G0378 | Hospital observation service, per hour | <1% | 407 | $68K |
| 80053 | Comprehensive metabolic panel | <1% | 15,443 | $67K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,131 | $65K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 282 | $61K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,864 | $59K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,848 | $54K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 40 | $54K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 348 | $42K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 169 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,569 | $34K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 213 | $32K |
| 73630 | <1% | 1,051 | $30K | |
| 93296 | <1% | 1,609 | $26K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 329 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,611 | $22K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 988 | $21K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,756 | $21K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 314 | $19K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 350 | $19K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,443 | $18K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 104 | $16K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,004 | $14K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 89 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 332 | $12K |
| 97161 | <1% | 330 | $12K | |
| 95811 | <1% | 13 | $12K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 151 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 143 | $9K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 102 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,239 | $8K |
| 76830 | Ultrasound, transvaginal | <1% | 120 | $7K |
| 88142 | <1% | 725 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,667 | $7K |
| 97035 | <1% | 334 | $6K | |
| 52000 | <1% | 13 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 302 | $6K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 566 | $6K |
| 62323 | <1% | 28 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 79 | $6K |
| 95951 | <1% | 18 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 37 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 148 | $5K |
| 93976 | <1% | 58 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 146 | $5K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 64 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 70 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 178 | $4K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 56 | $3K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 35 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,209 | $3K |
| 11721 | <1% | 1,237 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16 | $3K |
| 84484 | <1% | 3,759 | $3K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 782 | $3K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 5,048 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,484 | $3K |
| 97165 | <1% | 145 | $3K | |
| 73610 | <1% | 227 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 29 | $2K |
| 80061 | Lipid panel | <1% | 378 | $2K |
| 93922 | <1% | 68 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 350 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,092 | $2K |
| 73562 | <1% | 161 | $2K | |
| 83690 | <1% | 3,635 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 68 | $2K |
| 87631 | <1% | 32 | $2K | |
| 97162 | <1% | 65 | $2K | |
| 92558 | <1% | 146 | $2K | |
| 73110 | <1% | 95 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,831 | $1K |
| 97116 | <1% | 142 | $1K | |
| 97166 | <1% | 42 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 47 | $1K |
| 81001 | <1% | 4,685 | $1K | |
| 94060 | <1% | 29 | $1K | |
| 88342 | <1% | 70 | $1K | |
| 76801 | <1% | 15 | $1K | |
| J3490 | Unclassified drugs | <1% | 1,247 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 32 | $1K |
| 83735 | <1% | 2,123 | $1K | |
| 71250 | <1% | 44 | $1K | |
| 85027 | <1% | 476 | $985.46 | |
| 80069 | <1% | 104 | $879.25 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $873.96 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 504 | $869.82 |
| 94618 | <1% | 15 | $807.36 | |
| 73030 | <1% | 84 | $794.54 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 589 | $794.18 |
| 93298 | <1% | 30 | $704.53 | |
| 73130 | <1% | 55 | $671.36 | |
| 86803 | <1% | 18 | $604.05 | |
| G0008 | Administration of influenza virus vaccine | <1% | 58 | $585.46 |
| 93299 | <1% | 95 | $575.38 | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 14 | $434.99 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 119 | $434.79 |
| 80076 | <1% | 917 | $409.22 | |
| 76775 | <1% | 12 | $400.05 | |
| 76000 | <1% | 25 | $387.24 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,848 | $328.03 |
| 73140 | <1% | 20 | $321.88 | |
| 20610 | <1% | 36 | $320.43 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18 | $315.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12 | $275.00 |
| 73590 | <1% | 22 | $265.98 | |
| 81025 | <1% | 858 | $256.46 | |
| 93971 | <1% | 14 | $245.49 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,601 | $239.55 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 15 | $237.28 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,351 | $178.03 |
| 92134 | <1% | 114 | $176.46 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 212 | $163.48 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,768 | $160.66 |
| 84145 | <1% | 139 | $140.54 | |
| 86140 | <1% | 196 | $134.25 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 362 | $125.57 |
| 20611 | <1% | 13 | $116.48 | |
| 83655 | <1% | 15 | $107.24 | |
| 83605 | <1% | 370 | $102.97 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 14 | $102.54 |
| 74019 | <1% | 70 | $98.76 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 366 | $95.37 |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 17 | $86.97 |
| 84703 | <1% | 144 | $84.93 | |
| 82565 | <1% | 100 | $76.96 | |
| 81003 | <1% | 535 | $75.30 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 275 | $62.75 |
| 85379 | <1% | 57 | $62.44 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 16 | $56.57 |
| 51798 | <1% | 64 | $50.40 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 527 | $43.81 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 93 | $32.31 |
| 85652 | <1% | 227 | $30.22 | |
| 84702 | <1% | 13 | $30.10 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 39 | $24.16 |
| 87210 | <1% | 33 | $5.81 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 70 | $0.70 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 95 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 264 | $0.00 |
| 87510 | 0% | 120 | $0.00 | |
| 96376 | 0% | 210 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 783 | $0.00 |
| 94760 | 0% | 225 | $0.00 | |
| 87280 | 0% | 20 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 327 | $0.00 |
| C1769 | Guide wire | 0% | 393 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 146 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 201 | $0.00 |
| 87480 | 0% | 120 | $0.00 | |
| 82962 | 0% | 189 | $0.00 | |
| 82728 | 0% | 17 | $0.00 | |
| 92567 | 0% | 423 | $0.00 | |
| 87040 | 0% | 89 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 67 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 322 | $0.00 |
| 87088 | 0% | 85 | $0.00 | |
| 83880 | 0% | 81 | $0.00 | |
| 96127 | 0% | 25 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 54 | $0.00 |
| 86901 | 0% | 12 | $0.00 | |
| 82550 | 0% | 36 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 17 | $0.00 |
| 85730 | 0% | 48 | $0.00 | |
| 85018 | 0% | 94 | $0.00 | |
| 86850 | 0% | 12 | $0.00 | |
| 83615 | 0% | 16 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 171 | $0.00 |
| 90686 | 0% | 14 | $0.00 | |
| 73502 | 0% | 17 | $0.00 | |
| 87077 | 0% | 29 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 16 | $0.00 |
| V5266 | Battery for use in hearing device | 0% | 64 | $0.00 |
| 85049 | 0% | 70 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 216 | $0.00 |
| 74018 | 0% | 43 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 457 | $0.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 191 | $0.00 |
| 94729 | 0% | 16 | $0.00 | |
| 87660 | 0% | 120 | $0.00 | |
| 85610 | 0% | 387 | $0.00 | |
| 87186 | 0% | 137 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 34 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 281 | $0.00 |
| 84100 | 0% | 44 | $0.00 | |
| J7699 | Noc drugs, inhalation solution administered through dme | 0% | 12 | $0.00 |
| 86900 | 0% | 12 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 128 | $0.00 |
| 92557 | 0% | 32 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 13 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 64 | $0.00 |
| 99152 | 0% | 15 | $0.00 | |
| 84460 | 0% | 31 | $0.00 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 0% | 13 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| 84439 | 0% | 13 | $0.00 | |
| 94726 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCNAMEE, COURTNEY (DIRECTOR OF PAYER REVENUE MANAGEMEN)
| Provider | Location | Paid |
|---|---|---|
| Altru Health System | Grand Forks, ND | $491K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.